Compounds and Method for Cancer Therapy
Section: For Industry
Category(ies): Cancer Therapeutics
Reference #: BAPA422001
OTC Contact: Tracy L. Bruehs, J.D., M.S. (Directory Information | Send a Message)
Description
The present invention relates to compositions of matter and methods of inducing expression of an epigenetically silenced tumor suppressor gene, RASSF1A, in human cancer cells. It also relates to methods of treating an individual prophylactically or therapeutically, for cancer in which RASSF1A is epigenetically silenced.
Applications
- Application covers known and novel compositions of matter as well as methods to treat for cancer in which RASSF1A has been epigenetically silenced;
- Application covers methods to screen for drugs that induce RASSF1A expression in which RASSF1A has been epigenetically silenced.
- Compounds treat both androgen-sensitive and androgen-independent prostate cancer;
- Technology provides essential cancer treatment alternative therapy providing improvement over hormone ablation therapy, which only causes a temporary regression of tumor size and cells invariably become androgen-independent within 6-18 months;
- Compounds and methods have been shown to treat prostate, skin, lung, pancreatic, colon, breast and ovarian cancer cell lines in vitro;
- Administration of the compound is in a therapeutically effective amount, and can be by a variety or routes;
- Compounds can be synthesized with known methods and are derivatives or analogues of a naturally occurring plant extract with similar anti-cancer properties
Advantages
Stage of Development
Stage of Development: In vitro cell studies using PC3 and LNCaP prostate cell lines; epidermoid (!431), lung (A549), pancreatic (ASPC-1), colon (HT-29), breast (MCF-7), and ovarian (SKOV-3) cells
Inventors: Drs., Partha Banerjee, Shankar Jagadeesh, Milton Brown, Mikell Paige, and Kathryn Ditmer
Relevant Publications
Sinha, S., et al., Mahanine inhibits growth and induces apoptosis in prostate cancer cells through the deactivation of Akt and activation of caspases. Prostate 2006. 661257-65.
Patent Status
U.S. Patent Application Filed on October 23, 2006; PCT Application Filed on October 23, 2007
